



















































**Table 4-12. Summary of studies in rats.**

<b>Studies</b>	<b>Design: dose, duration and initial group size</b>	<b>Comments on study</b>	<b>Results male</b>	<b>Results female</b>
<b>Oral</b>				
F344 rats (NCI, 1979a)	500, 1000 or 2000 mg/kg, 5 days/wk, 78 weeks (mid- & high dose) or 103 weeks (low dose) 20/control group; 50/treatment group	Poor survival of high dose groups, small control group	No significant increase in tumors	No significant increase in tumors
BD IV rats (Ponomarev and Tomatis, 1978)	1,350 mg/kg prenatally and 500 mg/kg weekly postweaning until death Controls: 36–39, Dosed: 71–73	Limited dosage regimen, once/wk dosing, limited reporting	No significant increase in tumors	No significant increase in tumors
Sprague Dawley rats (Conti <i>et al.</i> 1988)	50 or 250 mg/kg, 4–5 days/wk for 52 weeks and held until death 40/dose group	Mortality in high dose females, short treatment duration, low doses, limited reporting	No significant increase in tumors	No significant increase in tumors
Sprague Dawley rats (Beliles <i>et al.</i> 1985)	125 or 250 ppm in drinking water (7.7 – 14mg/kg/day in males and 12 – 20.5 mg/kg/day in females) for 2 years Controls: 76 (m), 106 (f) Dosed: 50 (m), 70 (f)	Low doses, limited reporting;	No significant increase in tumors	Small increase in mammary fibroadenoma
<b>Inhalation</b>				
Sprague Dawley rats (Conti <i>et al.</i> 1988)	25, 50, 100, 200 or 300 ppm, 4 hrs/day, 5 days/wk for 52 weeks and held until death	Limited dosing regimen, limited reporting	No significant increase in tumors	malignant mammary tumors increased in multiple groups, with significant trend
Sprague Dawley rats (Jersey <i>et al.</i> 1978)	600 or 1,200/1,000 ppm, 6 hrs/day, 5 days/wk, for 18.3 months (males) or 20.7 months (females)	Original report and data not available in published literature; limited reporting in reviews, high incidence of pneumonia	No significant increase in tumors	Small increase in leukemia/lymphosarcoma, with a significant trend
Sprague Dawley rats (Cruzan <i>et al.</i> 1998)	50, 200, 500 or 1000 ppm, 6 hrs/day, 5 days/wk for 104 weeks	No major limitations	Positive dose-related trend in interstitial testicular tumors	Pituitary and malignant mammary tumors decreased in all dose groups.















occurred primarily 1 and 3 bases following adduct bypass, when the lesion is positioned in the major groove of the template-primer stem (Latham *et al.* 2000).

Similar replication assays have been performed using *E. coli* Klenow fragment, Sequenase 2.0, T4 polymerase holoenzyme, polymerase  $\alpha$ , and polymerase  $\beta$ , *in vitro*. In all instances, lesion bypass is sensitive to both the local sequence context and the chirality of the  $\alpha$ -N<sup>6</sup>-dA styrene-7,8-oxide adducts. For example, in the 5'-AXG-3' sequence, adducts having (*R*) stereochemistry are bypassed, whereas stereochemically-identical lesions in other sequence contexts are often poor substrates. Similarly, (*R*) vs. (*S*)  $\alpha$ -N<sup>6</sup>-dA adducts introduced within identical sequences are often bypassed nonequivalently. The degree of adduct-directed termination and translesion synthesis during replication is also dependent on the choice of polymerase. Templates that are poor substrates for bypass synthesis with one enzyme often read through much more efficiently when a different polymerase is used (Latham *et al.* 1995). Similar studies have been conducted using reconstituted *E. coli* Pol III. Replication is poorly processive and strongly terminated by styrene-7,8-oxide lesions in 33-mer templates, although the same enzyme shows efficient bypass of the same adducts in M13 DNA (Latham *et al.* 1996). No data are available regarding replication by Y-family polymerases, *in vitro*.

- Some DNA adducts are xenobiotic specific (see page 326, line 2) but many are not (e.g., methylated adducts). Furthermore adducts formed by oxidative damage can be formed by many agents. In the same paragraph (line 6), 8-hydroxy-2'-deoxyguanosine is listed among the adducts in styrene-exposed individuals, and this most definitely is not styrene-specific. Delete first sentence (about adducts in general, lines 3-4), note and group the styrene-specific adducts together, and move 8-OH-dG to the end of the list of adducts.
- Page 326, lines 11 and 12 [“N7-guanine adducts are the predominant type, but are efficiently repaired.... O<sup>6</sup>-guanine adducts.... but are persistent...”]: Delete “efficiently” and add “more” before persistent.
- “adducts may result in depurination, may cause single-strand breaks, or may be repaired directly” (page 326, lines 13-14). Delete “or may be repaired directly.”
- Page 326, line 19 should be GC to TA instead of GC to AT.
- Replace “adducted in” on page 326, line 29 with “bonded at” or “bound at” and “adducted” on page 326, line 28 and page 327, line 2 with “bonded” or “bound.”
- Delete lines 3-7 on page 327 (This text mentions the geometry of the N<sup>6</sup> adenine adducts and the GC to AT transition is not a major mutagenic lesion).

#### 16. Section 5.5 Mechanistic studies and considerations (General)

- Add information in Section 5.5.3 on cytotoxicity/epigenetic mechanisms. Additional discussion could be included that relates the cytotoxicity of styrene in susceptible Clara cells or in human bronchial epithelial cells to cellular proliferation and mechanisms of clonal expansion of styrene-induced, or spontaneous mutants. Bogen *et al.* (2008) publication on naphthalene is a good example of this mechanism. Suggested text follows:

In a report of deliberations of a scientific panel at the Naphthalene State-of-the-Science Symposium on the pathogenesis of respiratory tumor formation in rodents (Bogen *et al.* 2008), the following hypothesis for naphthalene-induced neoplasia was presented. Rats chronically exposed to naphthalene by inhalation (NTP 2000) had chronic nasal tissue damage associated with regenerative hyperplasia, atypical hyperplasia, and in a few cases, adenoma formation. This association supports the hypothesis that an increase in tumor incidence after naphthalene exposure is occurring through a cytotoxic mechanism. Chronic cytotoxicity can result in a clonal expansion of cells and increased susceptibility to malignant transformation. Further, this panel reported that elevated incidences of mouse lung tumors occurred only with exposure to

cytotoxic concentrations of naphthalene. Metabolic activation was required and mouse Clara cells had the greatest capacity to metabolize naphthalene. Clara cells were also highly susceptible to naphthalene-induced cytotoxicity. Therefore, this section discusses cytotoxicity of styrene metabolites as a possible mechanism of styrene-induced carcinogenesis.

- Add discussion of styrene metabolism to 4-vinylphenols that are further oxidized to quinone reactive intermediates. Quinones participate in reactive oxygen mediated damage and cytotoxicity. Similar to naphthalene, this cytotoxicity could be a mechanism of clonal expansion of initiated cells.
- NTP to research relevance of cytotoxicity and tumorigenicity of ethylbenzene in mice and rats (Chan *et al.* 1998; Stott *et al.* 2003; Seghir *et al.* (submitted for publication) in regard to mechanistic considerations for styrene.
- Discuss Roder-Stolinski *et al.* 2008. Styrene induces an inflammatory response in human lung epithelial cells via oxidative stress and NF- $\kappa$ B activation. This paper characterized the inflammatory response of human alveolar epithelial cells to styrene. They reported that human lung epithelial cells (A549 cell line) exposed to styrene ( $10^{-1}$  to  $10^6$   $\mu\text{g}/\text{m}^3$ ) via the gas phase for 20 h had significantly increased ( $\sim 1.4$  fold;  $P < 0.05$ ) release of the inflammatory mediator protein, monocyte chemoattractant protein (MCP-1) at  $10^2$   $\mu\text{g}/\text{m}^3$  and higher, which could be inhibited by antioxidants. Styrene exposure (at the same concentrations that caused an increased MCP-1 release) also increased GSTP1 mRNA expression, which was inhibited by pre-treatment with antioxidants and significantly ( $P < 0.05$ ) increased phosphorylation of NF- $\kappa$ B ( $10^{-1}$  to  $10^5$   $\mu\text{g}/\text{m}^3$ ) and  $\text{I}\kappa\text{B}$  ( $10^0$  to  $10^6$   $\mu\text{g}/\text{m}^3$ ). The authors suggested that the activation of NF- $\kappa$ B signaling by styrene was mediated via a redox-sensitive mechanism.

#### 17. Section 5.5.3

- Page 331, line 17: Add discussion of proposed mechanism that discusses a possible role of styrene-induced elevation in prolactin levels as a potential mechanism for the induction of breast cancer.
- Add a brief discussion of epoxides in mammary tissue (role of CYP1B1) in Section 5.5 on page 325. Several chemicals associated with induction of mammary tumors are epoxides or are metabolized to epoxides (includes glycidol, benzene, 1,3-butadiene, and ethylene oxide; see Dunnick *et al.* 1995), and it has been hypothesized that the mammary gland may efficiently metabolize chemicals to their epoxides (Bennett and Davis, 2002), and therefore, may be a target tissue for the induction of epoxide-induced tumors.
- Page 329: change subheading 5.5.3 to “Cytotoxic effects of styrene on mouse lung” (rather than styrene oxide)
- Section 5.5.3: Add additional text after line 17 on page 331 and to summary in Section 5.5.4. Suggested text as follows:

Similar to the first of the three factors put forward by Cohen *et al.* (2002) as possible mechanisms for the development of hyperplasia and lung tumors in mice (see above), Cruzan *et al.* (2002) proposed that interspecies differences in styrene toxicity are most likely explained through CYP2F-generated metabolites (2F2 in mice, 2F4 in rats, and 2F1 in humans). They noted that almost all of the effects of cytotoxicity and tumor formation were seen in tissues that are high in CYP2F isoforms and that CYP2F inhibitors prevented cytotoxicity (see Section 5.1.3.4). Ring-oxidation metabolites, including 4-vinylphenol, are  $\sim 6$ -fold higher in mice compared with rats, and 4-vinylphenol is more potent than styrene-7,8-oxide as a pneumotoxicant (see Section 5.1.3.4). Also, styrene metabolism occurs primarily in Clara cells (see Sections 5.1.3.3 and 5.1.3.4), and mice produce higher levels of toxic metabolites (*R*-styrene-7,8-oxide, 4-vinylphenol, and oxidized reactive intermediates of 4-vinylphenol), and



have a lower level of epoxide hydrolase activity than rats or humans (see Sections 5.1.3.1 and 5.1.3.2). They stated that PBPK models predict that human do not generate sufficient levels of these metabolites in the terminal bronchioles to reach toxic levels. Cruzan stated that the tumor profile of styrene suggests a non-genotoxic mode of action since he felt that the tumors in animals, were common, reported in only one species and one site, did not occur at the 12 month sacrifice, and were associated with organ toxicity and cell turnover. Studies published after Cruzan's 2002 proposal that evaluated the role of CYP2F2, ring-oxidized metabolites, and cytotoxicity in the lung are discussed in Sections 5.1.3.4 and 5.2.2.2).

Report Approved Redacted Date Aug 26 2008  
David Phillips, Ph.D., D.Sc. (Chair)

## References<sup>1</sup>

1. Azuma Y, Nobuhara Y, Date K, Ohno K, Tanaka K, Hirano S, Kobayashi K, Sakurai T, Chiba M, Yamada T. 2000. Biological evaluation of styrene oligomers for endocrine-disrupting effects (II). *J Food Hyg Soc Japan* 41: 109-115.
2. Bachmann S, Hellwig J, Jackh R, Christian MS. 1998. Uterotrophic assay of two concentrations of migrates from each of 23 polystyrenes administered orally (by gavage) to immature female Wistar rats. *Drug Chem Toxicol* 21 Suppl 1: 1-30.
3. Baldwin RM, Shultz MA, Buckpitt AR. 2005. Bioactivation of the pulmonary toxicants naphthalene and 1-nitronaphthalene by rat CYP2F4. *J Pharmacol Exp Ther* 312(2): 857-65.
4. Bennett LM, Davis BJ. 2002. Identification of mammary carcinogens in rodent bioassays. *Environ Mol Mutagen* 39(2-3): 150-7.
5. Berode M, Droz PO, Guillemin M. 1985. Human exposure to styrene. VI. Percutaneous absorption in human volunteers. *Int Arch Occup Environ Health* 55(4): 331-6.
6. Bieche I, Narjoz C, Asselah T, Vacher S, Marcellin P, Lidereau R, Beaune P, de Waziers I. 2007. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1, CYP2 and CYP3 families in 22 different human tissues. *Pharmacogenet Genomics* 17(9): 731-42.
7. Bloomfield CD, Lindquist LL, Brunning RD, Yunis JJ, Coccia PF. 1978. The Philadelphia chromosome in acute leukemia. *Virchows Arch B Cell Pathol* 29(1-2): 81-91.
8. Boers JE, Ambergen AW, Thunnissen FB. 1999. Number and proliferation of clara cells in normal human airway epithelium. *Am J Respir Crit Care Med* 159(5 Pt 1): 1585-91.
9. Bogen KT. 1994. Models based on steady-state in vitro dermal permeability data underestimate short-term in vivo exposures to organic chemicals in water. *J Expo Anal Environ Epidemiol* 4(4): 457-475.
10. Bogen KT, Benson JM, Yost GS, Morris JB, Dahl AR, Clewell HJ, Krishnan K, Omiecinski CJ. 2008. Naphthalene metabolism in relation to target tissue anatomy, physiology, cytotoxicity, and tumorigenic mechanism of action. *Regul Toxicol Pharmacol* 51: S27-S36.
11. Brooks SM, Anderson L, Emmett E, Carson A, Tsay JY, Elia V, Buncher R, Karbowski R. 1980. The effects of protective equipment on styrene exposure in workers in the reinforced plastics industry. *Arch Environ Health* 35(5): 287-94.
12. Brown HS. 1985. Estimation of human daily dose of volatile organic contaminants in drinking water. In *Chemical Safety and Regulations Compliance, Proceedings Course. Meeting Date, 1983*. Homburger F, Marquis JK, eds. Switzerland: Karger. p. 42-49.
13. Burkova T, Bainova A, Kapurdov V. 1982. Occupational risk in repeated dermal contact with styrene. *Problemi na Khigienata* 7: 51-59.
14. Chan PC, Hasemani JK, Mahleri J, Aranyi C. 1998. Tumor induction in F344/N rats and B6C3F1 mice following inhalation exposure to ethylbenzene. *Toxicol Lett* 99(1): 23-32.
15. Chen S-S. Styrene Plastics. In: Kirk-Othmer Encyclopedia of Chemical Technology. 5<sup>th</sup> Edition.

---

<sup>1</sup> New literature identified by the expert panel

16. Colburn T, Dumanoski D, Myer JP. 1996. *Our Stolen Future: How We Are Threatening Our Fertility, Intelligence and Survival*: Dutton/Plume.
17. Csanády GA, Kessler W, Hoffmann HD, Filser JG. 2003. A toxicokinetic model for styrene and its metabolite styrene-7,8-oxide in mouse, rat and human with special emphasis on the lung. *Toxicol Lett* 138(1-2): 75-102.
18. Date K, Ohno K, Azuma Y, Hirano S, Kobayashi K, Sakurai T, Nobuhara Y, Yamada T. 2002. Endocrine-disrupting effects of styrene oligomers that migrated from polystyrene containers into food. *Food Chem Toxicol* 40(1): 65-75.
19. Delzell E, Sathiakumar N, Graff J, Matthews R. 2005. Styrene and ischemic heart disease mortality among synthetic rubber industry workers. *J Occup Environ Med* 47(12): 1235-43. (Supported by the Styrene Information Research Center. Authors affiliated with University of Alabama at Birmingham, AL; Wayne State University, MI.)
20. Delzell E, Sathiakumar N, Graff J, Macaluso M, Maldonado G, Matthews R. 2006. An updated study of mortality among North American synthetic rubber industry workers. *Res Rep Health Eff Inst*(132): 1-63; discussion 65-74.
21. Ding X, Kaminsky LS. 2003. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. *Annu Rev Pharmacol Toxicol* 43: 149-73.
22. Dunnick JK, Elwell MR, Huff J, Barrett JC. 1995. Chemically induced mammary gland cancer in the National Toxicology Program's carcinogenesis bioassay. *Carcinogenesis* 16(2): 173-9.
23. Dutkiewicz T, Tyras H. 1968. Skin absorption of toluene, styrene, and xylene by man. *Br J Ind Med* 25(3): 243.
24. Fail PA, Hines JW, Zacharewski T, Wu ZF, Borodinsky L. 1998. Assessment of polystyrene extract for estrogenic activity in the rat uterotrophic model and an in vitro recombinant receptor reporter gene assay. *Drug Chem Toxicol* 21 Suppl 1: 101-21.
25. Feng B, Zhou L, Passarelli M, Harris CM, Harris TM, Stone MP. 1995. Major groove (R)-alpha-(N6-adenyl)styrene oxide adducts in an oligodeoxynucleotide containing the human N-ras codon 61 sequence: conformations of the R(61,2) and R(61,3) sequence isomers from 1H NMR. *Biochemistry* 34(43): 14021-36.
26. Feng B, Voehler M, Zhou L, Passarelli M, Harris CM, Harris TM, Stone MP. 1996. Major groove (S)-alpha-(N6-adenyl)styrene oxide adducts in an oligodeoxynucleotide containing the human N-ras codon 61 sequence: conformations of the S(61,2) and S(61,3) sequence isomers from 1H NMR. *Biochemistry* 35(23): 7316-29.
27. Fukami T, Katoh M, Yamazaki H, Yokoi T, Nakajima M. 2008. Human cytochrome P450 2A13 efficiently metabolizes chemicals in air pollutants: naphthalene, styrene, and toluene. *Chem Res Toxicol* 21(3): 720-5.
28. Hennard C, Finneman J, Harris CM, Harris TM, Stone MP. 2001. The nonmutagenic (R)- and (S)-beta-(N(6)-adenyl)styrene oxide adducts are oriented in the major groove and show little perturbation to DNA structure. *Biochemistry* 40(33): 9780-91. (Supported by the NIH, the Vanderbilt Center in Molecular Toxicology, University of Wisconsin, NSF, and USDA. Authors affiliated with Vanderbilt University, TN.)
29. Hoet P, Lison D. 2008. Ototoxicity of toluene and styrene: state of current knowledge. *Crit Rev Toxicol* 38(2): 127-70.

30. Hukkanen J, Pelkonen O, Hakkola J, Raunio H. 2002. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung. *Crit Rev Toxicol* 32(5): 391-411.
31. Jacobs A. 1989. Benzene and leukaemia. *Br J Haematol* 72(2): 119-21.
32. Johanson G, Ernstgard L, Gullstrand E, Lof A, Osterman-Golkar S, Williams CC, Sumner SC. 2000. Styrene oxide in blood, hemoglobin adducts, and urinary metabolites in human volunteers exposed to (13)C(8)-styrene vapors. *Toxicol Appl Pharmacol* 168(1): 36-49. (Supported by the Styrene Information and Research Center. Authors affiliated with National Institute for Working Life, Sweden; University Hospital, Sweden; Arrhenius Laboratories for Natural Sciences, Sweden; CIIT, NC.)
33. Johnson AC. 2007. Relationship between styrene exposure and hearing loss: review of human studies. *Int J Occup Med Environ Health* 20(4): 315-25.
34. Kanuri M, Finneman J, Harris CM, Harris TM, Lloyd RS. 2001. Efficient nonmutagenic replication bypass of DNAs containing beta-adducts of styrene oxide at adenine N(6). *Environ Mol Mutagen* 38(4): 357-60.
35. Karlgren M, Miura S, Ingelman-Sundberg M. 2005. Novel extrahepatic cytochrome P450s. *Toxicol Appl Pharmacol* 207(2 Suppl): 57-61.
36. Kitamura S, Ohmegi M, Sanoh S, Sugihara K, Yoshihara S, Fujimoto N, Ohta S. 2003. Estrogenic activity of styrene oligomers after metabolic activation by rat liver microsomes. *Environ Health Perspect* 111(3): 329-34.
37. Latham GJ, Lloyd RS. 1994. Deoxynucleotide polymerization by HIV-1 reverse transcriptase is terminated by site-specific styrene oxide adducts after translesion synthesis. *J Biol Chem* 269(46): 28527-30.
38. Latham GJ, Harris CM, Harris TM, Lloyd RS. 1995. The efficiency of translesion synthesis past single styrene oxide DNA adducts in vitro is polymerase-specific. *Chem Res Toxicol* 8(3): 422-30.
39. Latham GJ, McNees AG, De Corte B, Harris CM, Harris TM, O'Donnell M, Lloyd RS. 1996. Comparison of the efficiency of synthesis past single bulky DNA adducts in vivo and in vitro by the polymerase III holoenzyme. *Chem Res Toxicol* 9(7): 1167-75.
40. Latham GJ, Forgacs E, Beard WA, Prasad R, Bebenek K, Kunkel TA, Wilson SH, Lloyd RS. 2000. Vertical-scanning mutagenesis of a critical tryptophan in the "minor groove binding track" of HIV-1 reverse transcriptase. Major groove DNA adducts identify specific protein interactions in the minor groove. *J Biol Chem* 275(20): 15025-33.
41. Le PT, Harris CM, Harris TM, Stone MP. 2000. Altered electrophoretic migration of polycyclic aromatic hydrocarbon and styrene oxide adducts at adenine N(6) correlates with adduct-induced structural disorder. *Chem Res Toxicol* 13(2): 63-71.
42. Michaud DS. 2004. Epidemiology of pancreatic cancer. *Minerva Chir* 59(2): 99-111.
43. Minamoto K, Nagano M, Inaoka T, Futatsuka M. 2002. Occupational dermatoses among fibreglass-reinforced plastics factory workers. *Contact Dermatitis* 46(6): 339-47.
44. Nhamburo PT, Kimura S, McBride OW, Kozak CA, Gelboin HV, Gonzalez FJ. 1990. The human CYP2F gene subfamily: identification of a cDNA encoding a new cytochrome P450, cDNA-directed expression, and chromosome mapping. *Biochemistry* 29(23): 5491-9.

45. Nichols WK, Mehta R, Skordos K, Mace K, Pfeifer AM, Carr BA, Minko T, Burchiel SW, Yost GS. 2003. 3-methylindole-induced toxicity to human bronchial epithelial cell lines. *Toxicol Sci* 71(2): 229-36.
46. Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. 2003. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Yakugaku Zasshi* 123(5): 369-75.
47. Ohno K, Azuma Y, Nakano S, Kobayashi T, Hirano S, Nobuhara Y, Yamada T. 2001. Assessment of styrene oligomers eluted from polystyrene-made food containers for estrogenic effects in in vitro assays. *Food Chem Toxicol* 39(12): 1233-41.
48. Ohno K, Azuma Y, Date K, Nakano S, Kobayashi T, Nagao Y, Yamada T. 2002. Estrogenicity of styrene oligomers and assessment of estrogen receptor binding assays. *Environ Health Perspect* 110(7): A384-5; author reply A385-6.
49. Ohno K, Azuma Y, Date K, Nakano S, Kobayashi T, Nagao Y, Yamada T. 2003. Evaluation of styrene oligomers eluted from polystyrene for estrogenicity in estrogen receptor binding assay, reporter gene assay, and uterotrophic assay. *Food Chem Toxicol* 41(1): 131-41.
50. Ohyama KI, Nagai F, Tsuchiya Y. 2001. Certain styrene oligomers have proliferative activity on MCF-7 human breast tumor cells and binding affinity for human estrogen receptor. *Environ Health Perspect* 109(7): 699-703.
51. Painter SL, Zegar IS, Tamura PJ, Bluhm S, Harris CM, Harris TM, Stone MP. 1999. Influence of the R(61,2)- and S(61,2)-alpha-(N6-adenyl)styrene oxide adducts on the A.C mismatched base pair in an oligodeoxynucleotide containing the human N-ras codon 61. *Biochemistry* 38(27): 8635-46.
52. Pelkonen O, Raunio H. 1997. Metabolic activation of toxins: tissue-specific expression and metabolism in target organs. *Environ Health Perspect* 105 Suppl 4: 767-74.
53. Priddy DB. Styrene. In: Kirk-Othmer Encyclopedia of Chemical Technology. 5<sup>th</sup> Edition.
54. Raunio H, Rautio A, Pelkonen O. 1999. The CYP2A subfamily: function, expression and genetic polymorphism. *IARC Sci Publ*(148): 197-207.
55. Roberts ES, Ashworth EI, Hollenberg, PF, 1998. Mechanism-based inactivation of cytochromes P450 2E1 and 2B1 by 5-phenyl-1-pentyne. *Arch Biochem Biophys* 354(2):295-302.
56. Roder-Stolinski C, Fischader G, Oostingh GJ, Feltens R, Kohse F, von Bergen M, Morbt N, Eder K, Duschl A, Lehmann I. 2008. Styrene induces an inflammatory response in human lung epithelial cells via oxidative stress and NF-kappaB activation. *Toxicol Appl Pharmacol*.
57. Sandell J, Marniemi J, Parkki MG, Aitio A. 1978. Effects of inhalation and cutaneous exposure to styrene on drug metabolism. *International Congress Series* 440(Ind. Environ Xenobiotics): 177-179.
58. Seliskar M, Rozman D. 2007. Mammalian cytochromes P450--importance of tissue specificity. *Biochim Biophys Acta* 1770(3): 458-66.
59. Sheets PL, Yost GS, Carlson GP. 2004. Benzene metabolism in human lung cell lines BEAS-2B and A549 and cells overexpressing CYP2F1. *J Biochem Mol Toxicol* 18(2): 92-9.
60. Simeonov MF, Tamura PJ, Wilkinson AS, Harris CM, Harris TM, Stone MP. 2000. Sequence- and stereospecific conformational rearrangement of styrene oxide adducts located at A x C

- mismatched base pairs. *Biochemistry* 39(5): 924-37. (Supported by the NIH, the Vanderbilt Center in Molecular Toxicology, University of Wisconsin, NSF and the USDA. Authors affiliated with Bulgarian Academy of Sciences, Bulgaria; Vanderbilt University, TN.)
61. Simmonds AC, Ghanayem BI, Sharma A, Reilly CA, Millen B, Yost GS, Forkert PG. 2004. Bioactivation of 1,1-dichloroethylene by CYP2E1 and CYP2F2 in murine lung. *J Pharmacol Exp Ther* 310(3): 855-64.
  62. Smith CJ, Perfetti TA, Garg R, Hansch C. 2006. Utility of the mouse dermal promotion assay in comparing the tumorigenic potential of cigarette mainstream smoke. *Food Chem Toxicol* 44(10): 1699-706.
  63. Somers GI, Lindsay N, Lowdon BM, Jones AE, Freathy C, Ho S, Woodrooffe AJ, Bayliss MK, Manchee GR. 2007. A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes. *Drug Metab Dispos* 35(10): 1797-805.
  64. Stewart RD, Dodd HC, Baretta ED, Schaffer AW. 1968. Human exposure to styrene vapor. *Arch Environ Health* 16(5): 656-62.
  65. Stone MP, Feng B. 1996. Sequence and stereospecific consequences of major groove (N6-adenyl)-styrene oxide adducts in an oligodeoxynucleotide containing the human N-ras codon 61 sequence. *Magn Res Chem* 34: S105-S114.
  66. Stott WT, Johnson KA, Bahnemann R, Day SJ, McGuirk RJ. 2003. Evaluation of potential modes of action of inhaled ethylbenzene in rats and mice. *Toxicol Sci* 71(1): 53-66.
  67. Thum T, Erpenbeck VJ, Moeller J, Hohlfeld JM, Krug N, Borlak J. 2006. Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers. *Environ Health Perspect* 114(11): 1655-1661.
  68. Uhde E, Salthammer T. 2007. Impact of reaction products from building materials and furnishing on indoor air quality - A review of recent advances in indoor chemistry. *Atmos Environ* 41: 3111-3128.
  69. Yunis JJ. 1983. The chromosomal basis of human neoplasia. *Science* 221(4607): 227-36.
  70. Zhang JY, Wang Y, Prakash C. 2006. Xenobiotic-metabolizing enzymes in human lung. *Curr Drug Metab* 7(8): 939-48

## **Attachment 1 to Section 4 Subgroup Report. Excerpts on Comparisons with Historical Controls from the IARC Preamble and a Recent NTP 2008 Report**

### **Preamble to the *IARC Monographs* (amended January 2006)**

“It is generally not appropriate to discount a tumour response that is significantly increased compared with concurrent controls by arguing that it falls within the range of historical controls, particularly when historical controls show high between-study variability and are, thus, of little relevance to the current experiment. In analysing results for uncommon tumours, however, the analysis may be improved by considering historical control data, particularly when between-study variability is low. Historical controls should be selected to resemble the concurrent controls as closely as possible with respect to species, gender and strain, as well as other factors such as basal diet and general laboratory environment, which may affect tumour-response rates in control animals (Haseman *et al.* 1984; Fung *et al.* 1996; Greim *et al.* 2003).”

This may be found at the following link or obtained from WHO/IARC:  
<http://monographs.iarc.fr/ENG/Preamble/currentb3studiesanimals0706.php>

### **From the May 2008 NTP Technical Report on the Toxicology and Carcinogenesis Studies of Methylene Blue Trihydrate (CAS No. 7220-79-3) in F344/N Rats and B6C3F1 Mice (Gavage)**

“The concurrent control group represents the most valid comparison to the treated groups and is the only control group analyzed statistically in NTP bioassays. However, historical control data are often helpful in interpreting potential treatment-related effects, particularly for uncommon or rare neoplasm types. For meaningful comparisons, the conditions for studies in the historical database must be generally similar.”

**Attachment 2 to Subgroup Section 4 Report: Laboratory historical control incidence of leukemia-lymphosarcoma for Jersey *et al.* 1978**

<b>Study number</b>	<b>Males</b>	<b>Females</b>
1	3/80 (3.75%)	0/79 (0%)
2	0/25 (0%)	0/25 (0%)
3	None	2/159 (1.26%)
4	0/50 (0%)	None
5	2/90 (2.22%)	0/90 (0%)
6	5/85 (5.88%)	2/86 (2.32%)
7	4/112 (3.57%)	None
8	5/189 (2.64%)	5/189 (2.64%)
9	2/80 (2.5%)	2/80 (2.50%)
10	0/100 (0%)	0/100 (0%)
<b>Total</b>	<b>21/811 (2.59%)</b>	<b>11/808 (1.36%)</b>